Trials / Not Yet Recruiting
Not Yet RecruitingNCT06388551
A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral LPM526000133 Fumarate Capsules (LY03017) in Healthy Adult Subjects.
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Luye Pharma Group Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 1，randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.
Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
- Hallucinations and Delusions Associated With Parkinson Disease Psychosis
- Negative Symptoms of Schizophrenia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY03017 | single dose, administered orally |
| DRUG | LY03017-Placebo | single dose, administered orally |
Timeline
- Start date
- 2024-05-10
- Primary completion
- 2025-03-30
- Completion
- 2025-03-30
- First posted
- 2024-04-29
- Last updated
- 2024-04-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06388551. Inclusion in this directory is not an endorsement.